Manar Magdy Mahmoud Mahmoud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Manar Magdy Mahmoud Mahmoud has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Charlotte Held Gotfredsen
Department of Chemistry, Technical University of Denmark, Kongens Lyngby, Denmark
2 shared publications - José Manuel Afonso Moreira
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
2 shared publications - Ling Ding
Department of Biotechnology and Biomedicine, Technical University of Denmark
2 shared publications - Luciano D. O. Souza
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, 2100 Copenhagen, Denmark
2 shared publications - Gundela Peschel
Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute, BioPilot Plant, Beutenbergstraße 11A, 07745, Jena, Germany
1 shared publication - Kah Yean Lum
Department of Biotechnology and Biomedicine, Technical University of Denmark, Søltofts Plads 221, Kgs. Lyngby DK-2800, Denmark
1 shared publication
Latest Publications
- Open Access
Antimicrobial and Cytotoxic Lysolipins I–M Isolated from Streptomyces sp. P8-2B18
Lysolipin I ( 1 ) is a highly bioactive xanthone with strong antibacterial and cytotoxic properties. Given the limited number of lysolipin analogues, discovery of new natural lysolipin derivatives is important for understanding their structure-activity relationships. A soil-derived Streptomyces sp. P8-2B18 harbors a putative lysolipin biosynthetic gene cluster and LC-MS based metabolomic analysis revealed the production of lysolipin I along with unreported analogues. Large-scale fermentation followed by isolation led to the discovery of four new analogues, lysolipins J-M ( 2 – 5 ), the structures of which were elucidated by mass spectrometric and NMR spectroscopic data analyses. Lysolipin L features a five-membered lactam F ring, which was unprecedented in reported lysolipins. Lysolipin M has a novel skeleton, with an extra methyl (Me-36) and a glycosyl group replacing a 1,3-oxane ring in lysolipin I. While lysolipins I, J and K displayed strong activity against Staphylococcus aureus and Aspergillus flavus with MIC values ranging from 0.25 to 4 μg/mL and lysolipin L showed only moderate activities, lysolipin M was inactive (>50 μg/mL). Lysolipins I–K showed potent cytotoxic activity against prostate cancer cell lines LNCaP and C4-2B, with IC 50 values in the submicromolar range. In contrast, lysolipin L exhibited no cytotoxicity and lysolipin M exhibited substantially reduced potency. Their broad, non-selective bioactivities restricted their applicability as therapeutic agents.
Open AccessAntimicrobial and Cytotoxic Lysolipins I–M Isolated from Streptomyces sp. P8-2B18
Lysolipin I ( 1 ) is a highly bioactive xanthone with strong antibacterial and cytotoxic properties. Given the limited number of lysolipin analogues, discovery of new natural lysolipin derivatives is important for understanding their structure-activity relationships. A soil-derived Streptomyces sp. P8-2B18 harbors a putative lysolipin biosynthetic gene cluster and LC-MS based metabolomic analysis revealed the production of lysolipin I along with unreported analogues. Large-scale fermentation followed by isolation led to the discovery of four new analogues, lysolipins J-M ( 2 – 5 ), the structures of which were elucidated by mass spectrometric and NMR spectroscopic data analyses. Lysolipin L features a five-membered lactam F ring, which was unprecedented in reported lysolipins. Lysolipin M has a novel skeleton, with an extra methyl (Me-36) and a glycosyl group replacing a 1,3-oxane ring in lysolipin I. While lysolipins I, J and K displayed strong activity against Staphylococcus aureus and Aspergillus flavus with MIC values ranging from 0.25 to 4 μg/mL and lysolipin L showed only moderate activities, lysolipin M was inactive (>50 μg/mL). Lysolipins I–K showed potent cytotoxic activity against prostate cancer cell lines LNCaP and C4-2B, with IC 50 values in the submicromolar range. In contrast, lysolipin L exhibited no cytotoxicity and lysolipin M exhibited substantially reduced potency. Their broad, non-selective bioactivities restricted their applicability as therapeutic agents.
- 9 April 2024
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 87 (4) , 1075-1083
Pepticinnamins N, O, and P, Nonribosomal Peptides from the Soil-Derived Streptomyces mirabilis P8-A2
Cinnamoyl moiety containing nonribosomal peptides represented by pepticinnamin E are a growing family of natural products isolated from different Streptomyces species and possess diverse bioactivities. The soil bacterium Streptomyces mirabilis P8-A2 harbors a cryptic pepticinnamin biosynthetic gene cluster, producing azodyrecins as major products. Inactivation of the azodyrecin biosynthetic gene cluster by CRISPR-BEST base editing led to the activation and production of pepticinnamin E (1) and its analogues, pepticinnamins N, O, and P (2-4), the structures of which were determined by detailed NMR spectroscopy, HRMS data, and Marfey's reactions. These new compounds did not show a growth inhibitory effect against the LNCaP and C4-2B prostate cancer lines, respectively.
- 9 April 2024
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 87 (4) , 1075-1083
Pepticinnamins N, O, and P, Nonribosomal Peptides from the Soil-Derived Streptomyces mirabilis P8-A2
Cinnamoyl moiety containing nonribosomal peptides represented by pepticinnamin E are a growing family of natural products isolated from different Streptomyces species and possess diverse bioactivities. The soil bacterium Streptomyces mirabilis P8-A2 harbors a cryptic pepticinnamin biosynthetic gene cluster, producing azodyrecins as major products. Inactivation of the azodyrecin biosynthetic gene cluster by CRISPR-BEST base editing led to the activation and production of pepticinnamin E (1) and its analogues, pepticinnamins N, O, and P (2-4), the structures of which were determined by detailed NMR spectroscopy, HRMS data, and Marfey's reactions. These new compounds did not show a growth inhibitory effect against the LNCaP and C4-2B prostate cancer lines, respectively.